WHO ICTRP trial
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors
RPCEC00000159 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Not Recruiting
Key facts
| Trial ID | RPCEC00000159 |
|---|---|
| Public title | EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors |
| Scientific title | Clinical evaluation of the VChTV Schedule with the EGF-based vaccine the treatment of patients suffering hormone-refractory prostate tumors |
| Primary sponsor | Centre of Molecular Immunology (CIM) |
| Secondary sponsors | Not applicable |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Cuba |
| Conditions | Hormone-refractory prostate tumors |
| Interventions | Study Group (Vaccine EGF): Vaccine in schedule Vaccine-Chemotherapy-Vaccine (VChTV) Day 1 Cyclophosphamide 200 mg/m2 by intravenous route. Day 4 EGF vaccine 2.4 mg by intramuscular route quarterly up to 4 doses and thereafter every 28 days… |
| Registration date | Jun 19, 2013 |
| Target size | 212 |
| Secondary IDs | IIC RD-EC077 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: